Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Unlabelled: Direct thrombin inhibitors, including argatroban, are increasingly used for anticoagulation during venovenous extracorporeal membrane oxygenation (VV ECMO). In many centers activated partial thromboplastin time (aPTT) is used for monitoring, but it can be affected by several confounders. The aim of this study was to evaluate the safety and efficacy of anticoagulation with argatroban titrated according to diluted thrombin time targets (hemoclot™ assay) compared to anti-Xa guided anticoagulation with unfractionated heparin (UFH).
Methods: This cohort study included adults at two tertiary care centers who required VV ECMO for severe COVID-19-related acute respiratory distress syndrome (CARDS). Patients received center-dependent argatroban or UFH for anticoagulation during ECMO. Argatroban was guided following a hemoclot™ target range of 0.4-0.6 μg/ml. UFH was guided by anti-factor Xa (antiXa) levels (0.2-0.3 IU/ml). The primary outcome was safety of argatroban compared to UFH, assessed by time to first clinically relevant bleeding event or death during ECMO. Secondary outcomes included efficacy (time to thromboembolism) and feasibility (proportion of anticoagulation targets within range).
Results: From 2019 to 2021 57 patients were included in the study with 27 patients (47 %) receiving argatroban and 30 patients (53 %) receiving UFH. The time to the first clinically relevant bleeding or death during ECMO was similar between groups (HR (argatroban vs. UFH): 1.012, 95 % CI 0.44-2.35, p = 0.978). Argatroban was associated with a decreased risk for thromboembolism compared to UFH (HR 0.494 (95 % CI 0.26-0.95; p = 0.034)). The overall proportion of anticoagulation within target ranges was not different between groups (46 % (23-54 %) vs. 46 % (37 %-57 %), p = 0.45).
Conclusion: Anticoagulation with argatroban according to hemoclot™ targets (0.4-0.6 μg/ml) compared to antiXa guided UFH (0.2-0.3 IU/ml) is safe and may prolong thromboembolism-free time in patients with severe ARDS requiring VV ECMO.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2024.02.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Timely Initiation of Argatroban Improves Prognosis in Patients With Acute Ischemic Stroke Attributed to Large Artery Atherosclerosis: A Cohort Study.
Brain Behav
August 2025
Department of Neurology, Nanshi Hospital of Nanyang, Nanyang, China.
Introduction: Previous studies have demonstrated the benefits of anticoagulant therapy in acute ischemic stroke (AIS) of large artery atherosclerosis (LAA) etiology, although no prior research has examined the impact of the timing of anticoagulation initiation in this population.
Methods: A retrospective cohort study was conducted to assess the effect of early argatroban administration on clinical outcomes in AIS with LAA. Patients were stratified into an early administration group and a late administration group based on the time from stroke onset to argatroban initiation: ≤24 h and >24 h.
Site-Specific Antithrombotic Therapy: 24-Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple-Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus.
Catheter Cardiovasc Interv
August 2025
Cardiac Investigation Unit, Auckland City Hospital, Auckland, New Zealand.
Background: DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site-specific thrombotic risk.
Aims: To assess the feasibility and safety of this novel device against a contemporary drug-eluting stent.
Methods: This prospective, multicenter randomized (1:1) trial included 202 patients assigned between the device group (DESyne BDS Plus) and the control group (DESyne X2).
Rapid-Onset Heparin-Induced Thrombocytopenia Leading to Cardiogenic Shock Due to Left Anterior Descending Artery Embolism During Transcatheter Aortic Valve Replacement.
Cureus
July 2025
Anesthesiology and Center for Outcomes Research, University of Texas Health Science Center, Houston, USA.
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune-mediated complication of heparin therapy, often resulting in thrombotic events despite adequate anticoagulation. Rapid-onset HIT is a particularly severe variant that occurs within 24 hours of re-exposure to heparin in sensitized individuals with circulating anti-platelet factor 4 (PF4)/heparin antibodies. Although rare, its potential for rapid progression and fatal outcomes necessitates a high index of clinical suspicion, especially in perioperative settings involving routine heparin use.
View Article and Find Full Text PDFRevisiting Heparin-Induced Thrombocytopenia Among Patients Undergoing Free Tissue Transfer: A Systematic Review.
J Reconstr Microsurg
August 2025
Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Boston, United States.
Introduction Heparin is frequently used to mitigate the risk of thrombosis in microsurgical free tissue transfer. Although rare, heparin-induced thrombocytopenia (HIT) is a severe, life-threatening complication that can arise in patients exposed to heparin products. This systematic review aims to examine patterns in demographics, flap characteristics, diagnostic approaches, and treatment protocols for HIT following free flap reconstruction.
View Article and Find Full Text PDFAnalysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database.
PLoS One
August 2025
Department of Comprehensive Strokology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Recombinant tissue-type plasminogen activators (rtPA) effectively dissolve blood clots and improve symptoms in patients with acute ischemic stroke and myocardial infraction. Although rtPA are used in patients taking antiplatelets or anticoagulants to improve clinical outcomes, combination therapy may increase the risk of hemorrhagic transformation (HT) and intracerebral hemorrhage (ICH). However, few studies have investigated the risk of HT and ICH associated with these combination therapies.
View Article and Find Full Text PDF